Lee B, Wang Y, Carlson SA, Greenlund KJ, Lu H, Liu Y, et al. National, state-level, and county-level prevalence estimates of adults aged >/=18 years self-reporting a lifetime diagnosis of depression – United States, 2020. MMWR Morb Mortal Wkly Rep. 2023;72:644–50.
Gaynes BN, Warden D, Trivedi MH, Wisniewski SR, Fava M, Rush AJ. What did STAR*D teach us? Results from a large-scale, practical, clinical trial for patients with depression. Psychiatric services (Washington, DC). 2009;60:1439–45.
Filatova EV, Shadrina MI, Slominsky PA. Major depression: one brain, one disease, one set of intertwined processes. Cells. 2021;10:1283.
Cathomas F, Murrough JW, Nestler EJ, Han MH, Russo SJ. Neurobiology of resilience: interface between mind and body. Biol Psychiatry. 2019;86:410–20.
Hodes GE, Pfau ML, Leboeuf M, Golden SA, Christoffel DJ, Bregman D, et al. Individual differences in the peripheral immune system promote resilience versus susceptibility to social stress. Proc Natl Acad Sci USA. 2014;111:16136–41.
Pfau ML, Menard C, Cathomas F, Desland F, Kana V, Chan KL, et al. Role of monocyte-derived MicroRNA106b∼25 in resilience to social stress. Biol Psychiatry. 2019;86:474–82.
Cathomas F, Lin HY, Chan KL, Li L, Parise LF, Alvarez J, et al. Circulating myeloid-derived MMP8 in stress susceptibility and depression. Nature. 2024;626:1108–15.
Köhler CA, Freitas TH, Maes M, de Andrade NQ, Liu CS, Fernandes BS, et al. Peripheral cytokine and chemokine alterations in depression: a meta-analysis of 82 studies. Acta Psychiatr Scand. 2017;135:373–87.
Foley ÉM, Parkinson JT, Mitchell RE, Turner L, Khandaker GM. Peripheral blood cellular immunophenotype in depression: a systematic review and meta-analysis. Mol Psychiatry. 2022.
Raison CL, Rutherford RE, Woolwine BJ, Shuo C, Schettler P, Drake DF, et al. A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression: the role of baseline inflammatory biomarkers. JAMA Psychiatry. 2013;70:31–41.
Bekhbat M, Chu K, Le NA, Woolwine BJ, Haroon E, Miller AH, et al. Glucose and lipid-related biomarkers and the antidepressant response to infliximab in patients with treatment-resistant depression. Psychoneuroendocrinology. 2018;98:222–9.
Nutten S. Atopic dermatitis: global epidemiology and risk factors. Annals of nutrition and metabolism. 2015;66:8–16.
Yew YW, Thyssen JP, Silverberg JI. A systematic review and meta-analysis of the regional and age-related differences in atopic dermatitis clinical characteristics. J Am Acad Dermatol. 2019;80:390–401.
Armstrong AW, Mehta MD, Schupp CW, Gondo GC, Bell SJ, Griffiths CEM. Psoriasis prevalence in adults in the United States. JAMA dermatology. 2021;157:940–6.
He H, Bissonnette R, Wu J, Diaz A, Saint-Cyr Proulx E, Maari C, et al. Tape strips detect distinct immune and barrier profiles in atopic dermatitis and psoriasis. J Allergy Clin Immunol. 2021;147:199–212.
Brunner PM, He H, Pavel AB, Czarnowicki T, Lefferdink R, Erickson T, et al. The blood proteomic signature of early-onset pediatric atopic dermatitis shows systemic inflammation and is distinct from adult long-standing disease. J Am Acad Dermatol. 2019;81:510–9.
He H, Li R, Choi S, Zhou L, Pavel A, Estrada YD, et al. Increased cardiovascular and atherosclerosis markers in blood of older patients with atopic dermatitis. annals of allergy, asthma & immunology : official publication of the american college of allergy. Asthma, & Immunology. 2020;124:70–8.
Hansen BK, Olsson A, Zhang YM, Løvendorf MB, Skov L, Dyring-Andersen B. Proteins in skin and blood in patients with psoriasis: a systematic review of proteomic studies. Basel, Switzerland: Dermatology; 2023.
Simpson EL, Bieber T, Guttman-Yassky E, Beck LA, Blauvelt A, Cork MJ, et al. Two Phase 3 trials of dupilumab versus placebo in atopic dermatitis. N Engl J Med. 2016;375:2335–48.
Guttman-Yassky E, Bissonnette R, Ungar B, Suárez-Fariñas M, Ardeleanu M, Esaki H, et al. Dupilumab progressively improves systemic and cutaneous abnormalities in patients with atopic dermatitis. Journal of Allergy and Clinical Immunology. 2019;143:155–72.
Boguniewicz M, Beck LA, Sher L, Guttman-Yassky E, Thaci D, Blauvelt A, et al. Dupilumab improves asthma and sinonasal outcomes in adults with moderate to severe atopic dermatitis. The journal of allergy and clinical immunology In practice. 2021;9:1212–23.e6.
Mikhaylov D, Del Duca E, Olesen CM, He H, Wu J, Ungar B, et al. Transcriptomic profiling of tape-strips from moderate to severe atopic dermatitis patients treated with dupilumab. Dermatitis. 2021;32:S71–S80.
Paller AS, Simpson EL, Siegfried EC, Cork MJ, Wollenberg A, Arkwright PD, et al. Dupilumab in children aged 6 months to younger than 6 years with uncontrolled atopic dermatitis: a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet (London, England). 2022;400:908–19.
Simpson EL, Paller AS, Siegfried EC, Boguniewicz M, Sher L, Gooderham MJ, et al. Efficacy and safety of dupilumab in adolescents with uncontrolled moderate to severe atopic dermatitis: a phase 3 randomized clinical trial. JAMA dermatology. 2020;156:44–56.
Cork MJ, Thaci D, Eichenfield LF, Arkwright PD, Chen Z, Thomas RB, et al. Dupilumab safety and efficacy in a phase III open-label extension trial in children 6-11 years of age with severe atopic dermatitis. Dermatol Ther (Heidelb). 2023;13:2697–719.
Beck LA, Bissonnette R, Deleuran M, Nakahara T, Galus R, Coleman A, et al. Dupilumab in adults with moderate to severe atopic dermatitis: a 5-year open-label extension study. JAMA dermatology. 2024;160:805–12.
Siebert S, Loza MJ, Song Q, Mcinnes I, Sweet K. THU0052 ustekinumab and guselkumab treatment results in differences in serum IL17A, IL17F and CRP levels in psoriatic arthritis patients: a comparison from ustekinumab ph3 and guselkumab ph2 programs. BMJ Publishing Group Ltd. 2019.
Koschitzky M, Navrazhina K, Garshick MS, Gonzalez J, Han J, Garcet S, et al. Ustekinumab reduces serum protein levels associated with cardiovascular risk in psoriasis vulgaris. Exp Dermatol. 2022;31:1341–51.
Visvanathan S, Baum P, Vinisko R, Schmid R, Flack M, Lalovic B, et al. Psoriatic skin molecular and histopathologic profiles after treatment with risankizumab versus ustekinumab. Journal of Allergy and Clinical Immunology. 2019;143:2158–69.
Glickman JW, Dubin C, Han J, Dahabreh D, Garcet S, Krueger JG, et al. Comparing cutaneous molecular improvement with different treatments in atopic dermatitis patients. J Allergy Clin Immunol. 2020;145:1285–8.
First MB, Williams JBW, Karg RS, Spitzer RL Structured Clinical Interview for DSM-5 Disorders: Clinician Version (SCID-5-CV). Arlington, VA: American Psychiatric Association Publishing; (2015)
Rush AJ, Trivedi MH, Ibrahim HM, Carmody TJ, Arnow B, Klein DN, et al. The 16-Item Quick Inventory of Depressive Symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): a psychometric evaluation in patients with chronic major depression. Biol Psychiatry. 2003;54:573–83.
Severity scoring of atopic dermatitis: the SCORAD index. Consensus Report of the European Task Force on Atopic Dermatitis. Dermatology. 1993;186:23–31.
Carlin CS, Feldman SR, Krueger JG, Menter A, Krueger GG. A 50% reduction in the Psoriasis Area and Severity Index (PASI 50) is a clinically significant endpoint in the assessment of psoriasis. J Am Acad Dermatol. 2004;50:859–66.
Brunner PM, Suárez-Fariñas M, He H, Malik K, Wen HC, Gonzalez J, et al. The atopic dermatitis blood signature is characterized by increases in inflammatory and cardiovascular risk proteins. Sci Rep. 2017;7:8707.
Golden SA, Covington HE, Berton O, Russo SJ. A standardized protocol for repeated social defeat stress in mice. Nat Protoc. 2011;6:1183–91.
Cathomas F, Bevilacqua L, Ramakrishnan A, Kronman H, Costi S, Schneider M, et al. Whole blood transcriptional signatures associated with rapid antidepressant response to ketamine in patients with treatment resistant depression. Transl Psychiatry. 2022;12:12.
Mostafavi S, Battle A, Zhu X, Potash JB, Weissman MM, Shi J, et al. Type I interferon signaling genes in recurrent major depression: increased expression detected by whole-blood RNA sequencing. Mol Psychiatry. 2014;19:1267–74.
Pandya CD, Hoda N, Crider A, Peter D, Kutiyanawalla A, Kumar S, et al. Transglutaminase 2 overexpression induces depressive-like behavior and impaired TrkB signaling in mice. Mol Psychiatry. 2017;22:745–53.
Fang WQ, Ip JP, Li R, Ng YP, Lin SC, Chen Y, et al. Cdk5-mediated phosphorylation of Axin directs axon formation during cerebral cortex development. The Journal of neuroscience: the official journal of the Society for Neuroscience. 2011;31:13613–24.
Ye T, Fu AK, Ip NY. Emerging roles of Axin in cerebral cortical development. Front Cell Neurosci. 2015;9:217.
Sun K, Wang X, Fang N, Xu A, Lin Y, Zhao X, et al. SIRT2 suppresses expression of inflammatory factors via Hsp90-glucocorticoid receptor signalling. J Cell Mol Med. 2020;24:7439–50.
Liu R, Dang W, Du Y, Zhou Q, Jiao K, Liu Z. SIRT2 is involved in the modulation of depressive behaviors. Sci Rep. 2015;5:8415.
Erburu M, Munoz-Cobo I, Dominguez-Andres J, Beltran E, Suzuki T, Mai A, et al. Chronic stress and antidepressant induced changes in Hdac5 and Sirt2 affect synaptic plasticity. Eur Neuropsychopharmacol. 2015;25:2036–48.
Minic S, Cerovac N, Novakovic I, Gazikalovic S, Popadic S, Trpinac D. The impact of the IKBKG gene on the appearance of the corpus callosum abnormalities in incontinentia pigmenti. Diagnostics (Basel). 2023;13:1300.
Toriumi K, Miyashita M, Suzuki K, Tabata K, Horiuchi Y, Ishida H, et al. Role of glyoxalase 1 in methylglyoxal detoxification-the broad player of psychiatric disorders. Redox Biol. 2022;49:102222.
Gigante B, Bellis A, Visconti R, Marino M, Morisco C, Trimarco V, et al. Retrospective analysis of coagulation factor II receptor (F2R) sequence variation and coronary heart disease in hypertensive patients. Arterioscler Thromb Vasc Biol. 2007;27:1213–9.
Czubak-Prowizor K, Babinska A, Swiatkowska M. The F11 receptor (F11R)/junctional adhesion molecule-A (JAM-A) (F11R/JAM-A) in cancer progression. Mol Cell Biochem. 2022;477:79–98.
Sumazaki M, Shimada H, Ito M, Shiratori F, Kobayashi E, Yoshida Y, et al. Serum anti-LRPAP1 is a common biomarker for digestive organ cancers and atherosclerotic diseases. Cancer Sci. 2020;111:4453–64.
Palumbo V, Segat L, Padovan L, Amoroso A, Trimarco B, Izzo R, et al. Melusin gene (ITGB1BP2) nucleotide variations study in hypertensive and cardiopathic patients. BMC Med Genet. 2009;10:140.
Hartwig C, Veske A, Krejcova S, Rosenberger G, Finckh U. Plexin B3 promotes neurite outgrowth, interacts homophilically, and interacts with Rin. BMC Neurosci. 2005;6:53.
Yu XM, Askalan R, Keil GJ II, Salter MW. NMDA channel regulation by channel-associated protein tyrosine kinase Src. Science (New York, NY). 1997;275:674–8.
Zan L, Zhang X, Xi Y, Wu H, Song Y, Teng G, et al. Src regulates angiogenic factors and vascular permeability after focal cerebral ischemia-reperfusion. Neuroscience. 2014;262:118–28.
Verghese PB, Sasaki Y, Yang D, Stewart F, Sabar F, Finn MB, et al. Nicotinamide mononucleotide adenylyl transferase 1 protects against acute neurodegeneration in developing CNS by inhibiting excitotoxic-necrotic cell death. Proc Natl Acad Sci USA. 2011;108:19054–9.
Schenone S, Manetti F, Botta M. SRC inhibitors and angiogenesis. Curr Pharm Des. 2007;13:2118–28.
Jabbari A, Suarez-Farinas M, Fuentes-Duculan J, Gonzalez J, Cueto I, Franks AG Jr., et al. Dominant Th1 and minimal Th17 skewing in discoid lupus revealed by transcriptomic comparison with psoriasis. J Invest Dermatol. 2014;134:87–95.
Renert-Yuval Y, Pavel AB, Del Duca E, Facheris P, Pagan AD, Bose S, et al. Scalp biomarkers during dupilumab treatment support Th2 pathway pathogenicity in alopecia areata. Allergy. 2023;78:1047–59.
Chiricozzi A, Suarez-Farinas M, Fuentes-Duculan J, Cueto I, Li K, Tian S, et al. Increased expression of interleukin-17 pathway genes in nonlesional skin of moderate-to-severe psoriasis vulgaris. Br J Dermatol. 2016;174:136–45.
Zhao YT, Deng J, Liu HM, Wei JY, Fan HT, Liu M, et al. Adaptation of prelimbic cortex mediated by IL-6/STAT3/Acp5 pathway contributes to the comorbidity of neuropathic pain and depression in rats. J Neuroinflammation. 2022;19:144.
Khattri S, Shemer A, Rozenblit M, Dhingra N, Czarnowicki T, Finney R, et al. Cyclosporine in patients with atopic dermatitis modulates activated inflammatory pathways and reverses epidermal pathology. J Allergy Clin Immunol. 2014;133:1626–34.
Brunner PM, Israel A, Leonard A, Pavel AB, Kim HJ, Zhang N, et al. Distinct transcriptomic profiles of early-onset atopic dermatitis in blood and skin of pediatric patients. Annals of Allergy, Asthma & Immunology. 2019;122:318–30.e3.
Khattri S, Brunner PM, Garcet S, Finney R, Cohen SR, Oliva M, et al. Efficacy and safety of ustekinumab treatment in adults with moderate-to-severe atopic dermatitis. Exp Dermatol. 2017;26:28–35.
Pavel AB, Song T, Kim HJ, Del Duca E, Krueger JG, Dubin C, et al. Oral Janus kinase/SYK inhibition (ASN002) suppresses inflammation and improves epidermal barrier markers in patients with atopic dermatitis. J Allergy Clin Immunol. 2019;144:1011–24.
Krishnan V, Han MH, Graham DL, Berton O, Renthal W, Russo SJ, et al. Molecular adaptations underlying susceptibility and resistance to social defeat in brain reward regions. Cell. 2007;131:391–404.
Li L, Durand-de Cuttoli R, Aubry AV, Burnett CJ, Cathomas F, Parise LF, et al. Social trauma engages lateral septum circuitry to occlude social reward. Nature. 2023;613:696–703.
Yadav SK, Ahmad R, Moshfegh CM, Sankarasubramanian J, Joshi V, Elkhatib SK, et al. Repeated social defeat stress induces an inflammatory gut milieu by altering the mucosal barrier integrity and gut microbiota homeostasis. Biol Psychiatry Glob Open Sci. 2023;3:824–36.
Menard C, Pfau ML, Hodes GE, Kana V, Wang VX, Bouchard S, et al. Social stress induces neurovascular pathology promoting depression. Nat Neurosci. 2017;20:1752–60.
Li YJ, Xu M, Gao ZH, Wang YQ, Yue Z, Zhang YX, et al. Alterations of serum levels of BDNF-related miRNAs in patients with depression. PLoS ONE. 2013;8:e63648.
Felger JC, Lotrich FE. Inflammatory cytokines in depression: neurobiological mechanisms and therapeutic implications. Neuroscience. 2013;246:199–229.
Roohi E, Jaafari N, Hashemian F. On inflammatory hypothesis of depression: what is the role of IL-6 in the middle of the chaos? J Neuroinflammation. 2021;18:45.
Myint AM, Leonard BE, Steinbusch HW, Kim YK. Th1, Th2, and Th3 cytokine alterations in major depression. J Affect Disord. 2005;88:167–73.
Song C, Halbreich U, Han C, Leonard BE, Luo H. Imbalance between pro- and anti-inflammatory cytokines, and between Th1 and Th2 cytokines in depressed patients: the effect of electroacupuncture or fluoxetine treatment. Pharmacopsychiatry. 2009;42:182–8.
Park HJ, Shim HS, An K, Starkweather A, Kim KS, Shim I. IL-4 Inhibits IL-1beta-Induced Depressive-Like Behavior and Central Neurotransmitter Alterations. Mediators Inflamm. 2015;2015:941413.
Kim SJ, Lee H, Joung HY, Lee G, Lee HJ, Shin MK, et al. T-bet deficient mice exhibit resistance to stress-induced development of depression-like behaviors. J Neuroimmunol. 2011;240-241:45–51.
Pavon L, Sandoval-Lopez G, Eugenia Hernandez M, Loria F, Estrada I, Perez M, et al. Th2 cytokine response in Major Depressive Disorder patients before treatment. J Neuroimmunol. 2006;172:156–65.
Oyamada HAA, Cafasso M, Vollmer CM, Alvim F, Lopes LM, Castro C, et al. Major depressive disorder enhances Th2 and Th17 cytokines in patients suffering from allergic rhinitis and asthma. Int Arch Allergy Immunol. 2021;182:1155–68.
Fulle L, Offermann N, Hansen JN, Breithausen B, Erazo AB, Schanz O, et al. CCL17 exerts a neuroimmune modulatory function and is expressed in hippocampal neurons. Glia. 2018;66:2246–61.
Ghosh R, Kumar PK, Mitra P, Purohit P, Nebhinani N, Sharma P. Circulating T helper 17 and IFN-gamma positive Th17 cells in major depressive disorder. Behav Brain Res. 2020;394:112811.
Kim JW, Kim YK, Hwang JA, Yoon HK, Ko YH, Han C, et al. Plasma levels of IL-23 and IL-17 before and after antidepressant treatment in patients with major depressive disorder. Psychiatry Investig. 2013;10:294–9.
Davami MH, Baharlou R, Ahmadi Vasmehjani A, Ghanizadeh A, Keshtkar M, Dezhkam I, et al. Elevated IL-17 and TGF-β serum levels: a positive correlation between T-helper 17 cell-related pro-inflammatory responses with major depressive disorder. Basic Clin Neurosci. 2016;7:137–42.
Chen Y, Jiang T, Chen P, Ouyang J, Xu G, Zeng Z, et al. Emerging tendency towards autoimmune process in major depressive patients: a novel insight from Th17 cells. Psychiatry Res. 2011;188:224–30.
Schiweck C, Valles-Colomer M, Arolt V, Muller N, Raes J, Wijkhuijs A, et al. Depression and suicidality: A link to premature T helper cell aging and increased Th17 cells. Brain Behav Immun. 2020;87:603–9.
Paul ER, Schwieler L, Erhardt S, Boda S, Trepci A, Kampe R, et al. Peripheral and central kynurenine pathway abnormalities in major depression. Brain Behav Immun. 2022;101:136–45.
Agudelo LZ, Femenia T, Orhan F, Porsmyr-Palmertz M, Goiny M, Martinez-Redondo V, et al. Skeletal muscle PGC-1alpha1 modulates kynurenine metabolism and mediates resilience to stress-induced depression. Cell. 2014;159:33–45.
Nikkheslat N, Zunszain PA, Horowitz MA, Barbosa IG, Parker JA, Myint AM, et al. Insufficient glucocorticoid signaling and elevated inflammation in coronary heart disease patients with comorbid depression. Brain Behav Immun. 2015;48:8–18.
Song P, Ramprasath T, Wang H, Zou MH. Abnormal kynurenine pathway of tryptophan catabolism in cardiovascular diseases. Cell Mol Life Sci. 2017;74:2899–916.
Correia AS, Vale N. Tryptophan metabolism in depression: a narrative review with a focus on serotonin and kynurenine pathways. Int J Mol Sci. 2022;23:8493.
Beurel E, Medina-Rodriguez EM, Jope RS. Targeting the adaptive immune system in depression: focus on T helper 17 cells. Pharmacol Rev. 2022;74:373–86.
Chai HH, Fu XC, Ma L, Sun HT, Chen GZ, Song MY, et al. The chemokine CXCL1 and its receptor CXCR2 contribute to chronic stress-induced depression in mice. FASEB J. 2019;33:8853–64.
Karshikoff B, Wahlen K, Astrom J, Lekander M, Holmstrom L, Wicksell RK. Inflammatory blood signature related to common psychological comorbidity in chronic pain. Biomedicines. 2023;11:713.
Cork MJ, Eckert L, Simpson EL, Armstrong A, Barbarot S, Puig L, et al. Dupilumab improves patient-reported symptoms of atopic dermatitis, symptoms of anxiety and depression, and health-related quality of life in moderate-to-severe atopic dermatitis: analysis of pooled data from the randomized trials SOLO 1 and SOLO 2. J Dermatolog Treat. 2020;31:606–14.
Koya T, Sakai N, Sasaki T, Shinbori K, Nagai A, Kimura Y, et al. Effect of dupilumab on depression in asthma with eosinophilic chronic rhinosinusitis in the Japanese population. Int Arch Allergy Immunol. 2022;183:289–97.
Lonndahl L, Lundqvist M, Bradley M, Johansson EK. Dupilumab significantly reduces symptoms of prurigo nodularis and depression: a case series. Acta Derm Venereol. 2022;102:adv00754.
Eilat E, Mendlovic S, Doron A, Zakuth V, Spirer Z. Increased apoptosis in patients with major depression: A preliminary study. Journal of immunology (Baltimore, Md : 1950). 1999;163:533–4.
McKernan DP, Dinan TG, Cryan JF. Killing the Blues: a role for cellular suicide (apoptosis) in depression and the antidepressant response? Prog Neurobiol. 2009;88:246–63.
McMurray KM, Distler MG, Sidhu PS, Cook JM, Arnold LA, Palmer AA, et al. Glo1 inhibitors for neuropsychiatric and anti-epileptic drug development. Biochem Soc Trans. 2014;42:461–7.
Distler MG, Plant LD, Sokoloff G, Hawk AJ, Aneas I, Wuenschell GE, et al. Glyoxalase 1 increases anxiety by reducing GABAA receptor agonist methylglyoxal. J Clin Invest. 2012;122:2306–15.
Annam J, Galfalvy HC, Keilp JG, Simpson N, Huang YY, Nandakumar R, et al. Plasma cytokine and growth factor response to acute psychosocial stress in major depressive disorder. J Psychiatr Res. 2024;169:224–30.
Chang J, Jiang T, Shan X, Zhang M, Li Y, Qi X, et al. Pro-inflammatory cytokines in stress-induced depression: Novel insights into mechanisms and promising therapeutic strategies. Prog Neuropsychopharmacol Biol Psychiatry. 2024;131:110931.
Osimo EF, Baxter LJ, Lewis G, Jones PB, Khandaker GM. Prevalence of low-grade inflammation in depression: a systematic review and meta-analysis of CRP levels. Psychol Med. 2019;49:1958–70.